5-HT3 Receptor Antagonists for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Comparison of Their Pharmacology and Clinical Efficacy
RE Gregory, DS Ettinger - Drugs, 1998 - Springer
In the mid-1980s it was discovered that serotonin (5-hydroxytryptamine; 5-HT) was at least
partially responsible for producing chemotherapy-induced nausea and vomiting. It was …
partially responsible for producing chemotherapy-induced nausea and vomiting. It was …
Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control
FM Schnell - The oncologist, 2003 - academic.oup.com
Nausea and vomiting are two of the most feared side effects of cancer chemotherapy and
radiotherapy. Chemotherapy-induced nausea and vomiting can be broadly categorized as …
radiotherapy. Chemotherapy-induced nausea and vomiting can be broadly categorized as …
[PDF][PDF] Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines
RJ Gralla, D Osoba, MG Kris, P Kirkbride… - Journal of Clinical …, 1999 - Citeseer
THE GOAL OF ANTIEMETIC therapy is to prevent nausea and vomiting completely. This
goal is achieved for many patients receiving chemotherapy or radiation therapy, and is …
goal is achieved for many patients receiving chemotherapy or radiation therapy, and is …
Reduction of cisplatin-induced emesis by a selective neurokinin-1–receptor antagonist
RM Navari, RR Reinhardt, RJ Gralla… - … England Journal of …, 1999 - Mass Medical Soc
Background The localization of substance P in brain-stem regions associated with vomiting,
and the results of studies in ferrets, led us to postulate that a neurokinin-1–receptor …
and the results of studies in ferrets, led us to postulate that a neurokinin-1–receptor …
Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone …
D Campos, JR Pereira, RR Reinhardt… - Journal of clinical …, 2001 - ascopubs.org
PURPOSE: The NK1-receptor antagonist MK-869 (L-754,030) has demonstrated antiemetic
activity in humans receiving chemotherapy. Objectives of the present trial included the first …
activity in humans receiving chemotherapy. Objectives of the present trial included the first …
Clinical Science Review: Comparative Review of 5-HT3 Receptor Antagonists in the Treatment of Acute Chemotherapy-Induced Nausea and Vomiting
PJ Hesketh - Cancer investigation, 2000 - Taylor & Francis
Abstract Since their introduction, 5-HT3 receptor antagonists have become the agents of
choice in the prevention of acute chemotherapy-induced nausea and vomiting and are …
choice in the prevention of acute chemotherapy-induced nausea and vomiting and are …
A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis
K Jordan, A Hinke, A Grothey, W Voigt, D Arnold… - Supportive Care in …, 2007 - Springer
Goals of work Comparing antiemetic efficacy of different 5-HT 3-receptor antagonists (5-HT 3
RAs) is difficult due to inter-study variability. Therefore, a meta-analysis was performed to …
RAs) is difficult due to inter-study variability. Therefore, a meta-analysis was performed to …
Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta‐analysis
V Piechotta, A Adams, M Haque… - Cochrane Database …, 2021 - cochranelibrary.com
Background About 70% to 80% of adults with cancer experience chemotherapy‐induced
nausea and vomiting (CINV). CINV remains one of the most distressing symptoms …
nausea and vomiting (CINV). CINV remains one of the most distressing symptoms …
Gastrointestinal toxicity of chemotherapeutic agents
EP Mitchell - Seminars in Oncology, 2006 - Elsevier
Chemotherapy-induced toxicities commonly occur in sites within the gastrointestinal (GI)
tract and account for dose-limiting effects. These toxicities are major contributing factors to …
tract and account for dose-limiting effects. These toxicities are major contributing factors to …
Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic …
EA Perez, P Hesketh, J Sandbach, J Reeves… - Journal of Clinical …, 1998 - ascopubs.org
PURPOSE The antiemetic effectiveness and safety of single-dose oral granisetron were
compared with intravenous (IV) ondansetron in chemotherapy-naive patients who received …
compared with intravenous (IV) ondansetron in chemotherapy-naive patients who received …